Yükleniyor... / Loading...
This study evaluates the drug PF-00299804 as a single agent in patients with advanced non-small cell lung cancer (NSCLC) who failed chemotherapy and Erlotinib. It included patients with measurable disease and tissue available for KRAS/EGFR testing. It was a Phase 2 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Advanced Non-Small Cell Lung Cancer (NSCLC) * Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib. * Prior treatment with no more than two chemotherapy regimens, including adjuvant or combined modality treatment. * Measurable disease . * Eastern Cooperative Oncology Group (ECOG) Performance status 0-2 * Tissue available for KRAS/ EGFR testing * Creatinine clearance \> 40 cc/min or serum creat \< 1.5 x ULN Exclusion Criteria: * Chemotherapy * Radiotherapy * Biological or investigational agents within 4 weeks of baseline disease assessment. * Patients who lack of tolerance of erlotinib therapy.